Skip to main
OMER

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros is poised for success with its innovative pipeline, potential catalysts through planned drug approvals in 2026, and recent favorable financial results including net income of $86.5 million in the fourth quarter of 2025. The company's recently granted J-code for its newly approved TA-TMA therapy should reduce reimbursement friction and help accelerate demand, a key factor in converting clinical interest into utilization in the orphan disease market. Combined with a strong market need and improved financial profile, Omeros is well-positioned for future growth and potential success for investors.

Bears say

Omeros is facing multiple risk factors, including clinical and regulatory risk, partnership risk, financial risk, commercial risk, legal and intellectual property risk, and market share risk. Although the company has recently announced its first commercial sales and shipments of YARTEMLEA, the first approved therapy for transplant-associated thrombotic microangiopathy, there is still uncertainty surrounding the success of its clinical-stage development programs and the potential for competition in the market. Additionally, the high level of risk involved in the biotechnology industry makes it difficult to accurately predict the company's future financial performance and market share.

Omeros (OMER) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Omeros (OMER) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.